In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.
The industry grew closer to federal legalization of the first psychedelic compounds for therapeutic use. With scientific, regulatory and corporate developments becoming daily news, it’s easy to wonder what 2021 will bring to this burgeoning new space.
“By the end of 2021, I expect the conversation about access to therapeutic outcomes using what were previously known as psychedelics to be a global conversation,” said Bruce Linton, former CEO and founder of cannabis giant Canopy Growth (NYSE: CGC).